输尿管镜活检可协助上尿路尿路上皮癌危险分层
马闰卓1,*, 邱敏1,*, 何为1, 杨斌1, 夏海缀1, 邹达1, 陆敏2, 马潞林1, 卢剑1,
北京大学第三医院1. 泌尿外科, 2. 病理科, 北京 100191
摘要

目的:分析输尿管镜活检对上尿路尿路上皮癌(upper tract urothelial carcinoma,UTUC)患者肿瘤级别、肌层浸润以及多灶性诊断的准确性,分析术后肿瘤级别及肌层浸润的相关因素,探讨输尿管镜活检对UTUC患者术前危险分层的可行性与必要性。方法:回顾性分析北京大学第三医院泌尿外科2014年1月至2016年12月间输尿管镜活检后行肾、输尿管全长及膀胱输尿管口袖状切除术患者的临床资料。结果:患者76例,男性31例(40.8%)、女性45例(59.2%),平均年龄64.5岁(31~88岁)。肿瘤位于左侧35例、右侧41例,肾盂39例、输尿管37例,症状为肉眼血尿者51例。术后病理提示低级别21例(27.6%)、高级别51例(67.1%),未确定级别4例(5.3%);非肌层浸润27例(35.5%)、肌层浸润47例(61.9%),无法确认是否浸润2例(2.6%);术后病理均为UTUC。在50名输尿管镜活检可判断肿瘤级别的患者中,活检病理对低级别尿路上皮癌诊断的敏感性、特异性和准确性分别为88.2%、69.7%和76.0%,阳性和阴性预测值分别为60.0%和92.0%。在27例活检病理可以判断是否有肌层浸润的患者中,5例活检报告为肌层浸润的UTUC患者术后病理结果均有肌层浸润,22例报告为非肌层浸润的患者术后肌层浸润和非肌层浸润各占50%,总准确性为59.3%。输尿管镜活检对于肿物多灶性诊断的准确性为61.0%。单因素分析显示,输尿管镜活检级别与术后UTUC级别相关( P=0.001),而性别、年龄、边侧、体重指数(body mass index,BMI)、血尿、术前肾小球滤过率估计值(estimated glomerular filtration rate,eGFR)、泌尿系积水、肿瘤大小、位置、多灶性及是否有蒂均与术后UTUC级别无显著相关性。输尿管镜活检病理高级别( P=0.02)、术前eGFR<90 mL/(min·1.73 m2)( P=0.025)以及病变位于肾盂( P=0.049)与肌层浸润显著相关,性别、年龄、边侧、BMI、血尿、泌尿系积水、肿瘤大小、多灶性及是否有蒂与其无显著相关性。结论:输尿管镜活检可协助对UTUC患者进行危险分层。

关键词: 尿路上皮癌; 输尿管镜检查; 活组织检查; 肺癌分级
中图分类号:R693.4 文献标志码:A 文章编号:1671-167X(2017)04-0632-06
Ureteroscope can assist risk stratification in upper tract urothelial carcinoma
MA Run-zhuo1,*, QIU Min1,*, HE Wei1, YANG Bin1, XIA Hai-zhui1, ZOU Da1, LU Min2, MA Lu-lin1, LU Jian1,
1.Department of Urology, 2. Department of Pathology, Peking University Third Hospital, Beijing 100191, China
△ Corresponding author’s e-mail, lujian@bjmu.edu.cn

*These authors contributed equally to this work

Abstract

Objective:To analyze the efficiency of ureteroscope and biopsy in the diagnosis of tumor grade, muscle-invasiveness and multifocality in suspected upper tract urinary carcinoma (UTUC) patients in order to find out whether it can be used in the risk stratification of UTUC patients.Methods:A retrospective study of 76 UTUC patients who underwent preoperative ureteroscope and/or biopsy and received radical nephroureterectomy in Peking University Third Hospital during January 2014 to December 2016 was undertaken.Results:In this study, 76 patients were included. There were 31 males (40.8%), and 45 females (59.2%). The median age was 64.5 years (31-88), and 51 patients had the symptom of hematuresis. The tumor was located in renal pelvis in 39 patients, and in ureter in 37 patients. Post-operative pathology confirmed that all the 76 patients included in this study suffered from UTUC, of whom 21 (21.6%) were of low-grade, 51 (67.1%) were of high-grade, 4 (5.3%) were undetermined, and 47 (61.9%) patients were muscle-invasive, and 27 (35.5%) were not, and 2 (2.6%) were undetermined. Among the 50 patients, in whom the grade of the tumor could be diagnosed by biopsy, the sensitivity, specificity, accuracy, positive predictive value and negative predictive value for low-grade tumor was 88.2%, 69.7%, 76.0%, 60.0% and 92.0%, respectively. Among the 27 patients, in whom the muscle-invasiveness could be diagnosed by biopsy, 5 patients were diagnosed with muscle-invasiveness, all confirmed by pathology after surgery and 22 patients were diagnosed with none muscle-invasiveness, turned out to be 50% muscle-invasive and 50% none-muscle invasive after surgery. The accuracy was 59.3%. The accuracy of ureteroscopic biopsy to diagnosis multifocality was 61.0%. On univariate ana-lysis, biopsy grade was associated with postoperative pathology ( P=0.001), while gender, age, side, body mass index (BMI), hematuresis, preoperative estimated glomerular filtration rate (eGFR), hydronephrosis, tumor size, location, multifocality and sessile were not associated with postoperative pathology grade. Biopsy grade ( P=0.02), preoperative eGFR<90 mL/(min·1.73 m2)( P=0.025) and tumor located in pelvis ( P=0.049) were associated with muscle invasiveness. Gender, age, side, BMI, hematuresis, hydronephrosis, tumor size, multifocality and sessile were not significantly associated with muscle invasiveness.Conclusion:Ureteroscope and biopsy can assist risk stratification in upper tract urothelial carcinoma patients.

Key words: Urothelial carcinoma; Ureteroscopy; Biopsy; Neoplasm grading

上尿路尿路上皮癌(upper tract urothelial carcinoma, UTUC)包括发生在肾盂和输尿管的尿路上皮恶性肿瘤, 在西方国家占所有尿路上皮癌的5%~10%, 在我国占所有尿路上皮癌的20%~30%[1, 2]。肾、输尿管全长及膀胱输尿管口袖状切除术(radical nephroureterectomy, RNU)是目前公认的治疗UTUC手术的金标准, 但近年来, UTUC的保留肾单位手术(kidney-sparing surgery, KSS)也逐渐开展起来, KSS包括输尿管镜肿瘤切除术、经皮肾镜肿瘤切除术和输尿管部分切除术。UTUC的KSS需要准确的术前肿瘤危险分层, 仅对低级别、非肌层浸润性的UTUC行内镜下治疗, 才能达到和RNU一致的肿瘤特异性生存率(cancer specific survival, CSS)[3]。因此, 在术前确切地将低级别、非肌层浸润的患者区分出来非常重要。

随着输尿管镜技术的进步, UTUC术前输尿管镜活检已经被指南推荐[4]。但国内尚缺乏术前输尿管镜活检对疑似UTUC患者病理类型、肿瘤级别、肿瘤浸润深度与肿瘤多发性判断准确性的研究。本研究总结了76例术前行输尿管镜活检的UTUC患者的临床资料, 并和RNU术后病理进行了对照分析, 现报道如下。

1 资料与方法
1.1 临床资料

回顾性分析2014年1月至2016年12月在北京大学第三医院泌尿外科于输尿管镜活检后行RNU术患者的临床资料, 本组共76例。术前肾小球滤过率估计值(estimated glomerular filtration rate, eGFR)用中国人群改良公式进行估算[5], 术前影像(泌尿系B超、CT或MRI)诊断肾积水39例, RNU术后病理显示76例患者均为UTUC。输尿管镜活检采用输尿管硬镜或软镜进行, 判断肾盂、输尿管是否存在多灶病变, 用异物钳或取石篮套取可疑病变部位3~5块组织送检。RNU术采用开放或腹腔镜辅助的方式, 活检与术后病理标本根据2004年世界卫生组织/国际泌尿病理联盟分类共识(World Health Organization/International Society of Urologic Pathology consensus classification)进行肿瘤学分级, 并判断是否有肌层浸润。

1.2 统计学方法

采用单因素二元Logistic回归对高级别、肌层浸润性UTUC的危险因素进行分析, 分类变量的分布采用卡方检验, 连续性变量的分布采用Mann-Whitney U检验。应用SPSS 17.0进行统计分析, P值均为双侧, P< 0.05为差异有统计学意义。

2 结果

本组76例患者, 男性31例(40.8%)、女性45例(59.2%), 平均年龄64.5岁(31~88岁), 中位体重指数(body mass index, BMI)23.7 kg/m2(15.9~35.0 kg/m2)。肿瘤位于左侧35例、右侧41例, 肾盂39例、输尿管37例, 症状表现为肉眼血尿者51例。平均术前eGFR为79.5 mL/(min· 1.73 m2)[18.9~172.0 mL/(min· 1.73 m2)]。影像学检查示肿瘤最大径平均3.1 cm(1.1~12.2 cm)。术后病理报告:低级别21例(27.6%), 高级别51例(67.1%), 未确定级别4例(5.3%); 非肌层浸润27例(35.5%), 肌层浸润47例(61.9%), 无法确认是否浸润2例(2.6%)。患者基本信息如表1所示。

表1 76例患者的临床和输尿管镜活检病理特征 Table 1 Preoperative clinical parameters and ureteroscope biopsy characteristics of 76 patients

76例行输尿管镜活检的患者中, 9例因取材过少、变形严重而无法判断肿物类型, 失败率11.8%。67例明确活检病理类型的患者中, 58例诊断为尿路上皮癌, 9例诊断为良性病变(5例坏死组织和4例炎性增生)。RNU术后病理提示76例患者全部为尿路上皮癌, 输尿管镜活检对病理类型判断准确性为85.2%。

58例输尿管活检诊断为尿路上皮癌的患者中, 8例因标本挤压严重而无法判断UTUC肿瘤级别, 其余50例均可判断。输尿管镜活检诊断为低级别17例、高级别33例, 术后病理诊断为低级别25例、高级别25例; 其中有10例输尿管镜活检诊断为低级别, 而术后病理诊断为高级别; 2例输尿管镜活检诊断为高级别, 而术后病理诊断为低级别。输尿管镜活检对低级别UTUC的诊断敏感性为88.2%, 特异性为69.7%, 准确性为76.0%, 阳性和阴性预测值分别为60.0%和92.0%。58例患者中, 27例经输尿管镜活检可以判断是否有肌层浸润, 其中5例活检报告为肌层浸润的UTUC患者, 术后病理结果均有肌层浸润, 而活检报告非肌层浸润的22例UTUC患者中, 50%术后病理报告为肌层浸润, 另50%为非肌层浸润, 准确性为59.3%。

本组76例患者中, 17例因肿物完全堵塞管腔或因输尿管下段狭窄无法进镜而未能判断多灶性。完成患侧输尿管镜活检的59例患者中, 输尿管镜诊断存在多发灶者20例、单发灶者39例, 最终病理显示多发灶9例、单发灶50例; 其中6例输尿管镜活检判断为单灶, 而术后病理结果报告多灶; 17例输尿管镜活检报告多灶, 术后病理报告为单灶。输尿管镜对于多发灶判断的敏感性为33.3%, 特异性为66.0%, 准确性为61.0%, 阳性和阴性预测值分别为15%和84.6%。

单因素Logistic回归分析发现, 只有术前输尿管镜活检级别与术后UTUC级别相关(P=0.001), 术前eGFR< 90 mL/(min· 1.73 m2)(P=0.025)、肿物位于肾盂(P=0.049)及活检高级别(P=0.020)与术后UTUC是否存在肌层浸润相关, OR值分别为3.14(95%CI:1.16~8.54)、3.35(95%CI:1.01~11.19)和4.07(95%CI:1.25~13.24)(表2)。

表2 UTUC患者临床因子预测肿瘤级别及肌层浸润的单因素Logistic回归分析 Table 2 Univariate Logistic regression analysis to evaluate the association between clinical factors and tumor grade and muscle-invasive
3 讨论
3.1 输尿管镜活检对UTUC肿瘤学级别的诊断

输尿管镜活检是RNU术前可行的对于肿瘤学分级最准确的检查, 文献报道其对于肿瘤级别判断的准确性为69%~90%[6]。Keeley等[7]回顾性分析了51例UTUC患者输尿管镜活检结果和术后病理的一致性, 除去9例无法判断活检级别的病例, 在30例低级别的患者中, 90%与术后病理一致; 在12例高级别的患者中, 91.6%与术后病理一致。Cle-ments 等[8]报道输尿管镜活检对于低级别肿瘤的敏感性和特异性分别为91%、60%, 其阳性预测值为54%, 阴性预测值为92%。

本组患者输尿管镜活检对病理分级判断的准确性以及其对低级别肿瘤判断的敏感性、特异性、阳性和阴性预测值与国外报道基本一致, 且显示出“ 偏向低级别” 的趋势。因此, 在根据输尿管镜活检病理级别选择KSS治疗时, 应持保守态度, 因为有40%的患者可能为高级别病变。相反, 如果输尿管镜活检诊断为高级别, 其术后病理诊断为低级别的可能性很低(8%), 应当进行RNU手术。

另有学者尝试分析高级别UTUC除输尿管镜活检级别外的其他危险因素, 比如Chen等[9]提出高龄和无蒂的肿瘤形态是G3级肿瘤的高危因素, 多因素Logistic回归分析显示两者风险比分别为 1.047(95%CI:1.023~1.072)和25.192(95%CI:13.445~47.205)。本研究单因素回归分析显示, 年龄与高级别UTUC无显著相关性, 与Clements等[8]报道相符, 但与Chen等[9]的报道不一致, 这可能是由于Chen等[9]采用1973年世界卫生组织的肿瘤学分级标准, 将肿瘤级别分为G1、G2、G3, 而本研究与Clements等[8]都采用2004世界卫生组织/国际泌尿病理联盟分类共识进行肿瘤学分级, 将肿瘤分为低级别和高级别。另外, 本研究提示, 输尿管镜检查时的肿物形态(平坦或有蒂)与术后肿瘤级别无显著相关性, 也与Chen等[9]的研究结果不同, 可能因为本研究肿物的形态主要靠输尿管镜判断, 而Chen等[9]对肿物形态的判定是根据术后的病理结果。尽管在输尿管或肾盂狭小的空间里, 输尿管镜很难完整观察到较大肿物的整体形态, 会导致对于肿物形态的判断失误, 但根据术后病理结果判断肿瘤形态对手术方式的选择并无意义。本研究表明, 除输尿管镜活检级别外, 其他临床因素, 如性别、年龄、边侧、BMI、血尿、术前eGFR、肾积水以及肿物大小、位置、多灶性、形态, 均与术后病理肿瘤级别无显著相关性。

因此, 输尿管镜活检对UTUC患者肿瘤级别的诊断准确率较高, 并且是术后肿瘤级别的唯一相关因素, 对于患者可否行KSS治疗具有重要参考价值。

3.2 输尿管镜活检对UTUC患者肌层浸润的诊断

由于肾盂及输尿管管壁较薄, CT和MRI均难以分辨病灶是否累及肌层, 术前影像只能通过观察病灶是否侵犯管壁外结构(如肾窦脂肪、肾实质、输尿管周围结构等)区分出T3期以上肿瘤。

输尿管镜活检对于UTUC患者病灶是否浸润肌层的诊断也存在困难。由于输尿管镜活检的取材深度难以达到平滑肌层, 本研究中仅50%患者可以判断是否有肌层浸润, 且活检结果为非肌层浸润的患者中, 术后病理报告为肌层浸润和非肌层浸润的比例各为50%, 对医生的判断帮助不大。而且输尿管镜活检只能判断取到的部分是否有肌层浸润, 而未取部分是否存在肌层浸润更无从判断。本研究结果表明, 如果活检结果为肌层浸润, 100%的患者术后病理确认存在肌层浸润, 因此, 对这部分患者, RNU治疗实属必要。

如何准确判断UTUC患者是否存在肌层浸润十分重要。有些学者尝试改进取活检设备[10, 11], 另一些学者则另辟蹊径, 尝试将一些患者的临床特征与辅助检查结果结合起来, 以提高对于肿瘤分期预测的准确性, 最常用的方法是通过术前活检级别预测肿瘤是否浸润肌层。Keeley等[7]分析了输尿管镜活检级别与术后肿瘤分期的关系, 在低级别患者中, 86.6%(26/30)为非肌层浸润(Ta或T1), 而在高级别患者中, 66.7%(8/12)为肌层浸润(T2或更高), 因此认为输尿管镜活检可以得到准确的预测分期。为进一步提高输尿管镜活检级别对肿瘤肌层浸润预测的准确性, Brien等[12]将尿细胞学检查肿瘤细胞阳性及影像学肾积水这两个因素与输尿管镜活检高级别联合起来, 使预测UTUC肌层浸润的敏感性达到89%, 如果3个危险因素全部为阴性, 对肌层浸润的阴性预测值达到100%。此外, 其他研究也表明, 男性患者、影像上的局部侵犯、无蒂病灶、单发病灶及病灶位于肾盂等均为肿瘤浸润肌层的危险因素[9, 13]

本组患者活检高级别与术后UTUC肌层浸润显著相关(P=0.020), OR值为4.07(95%CI:1.25~13.24)。此外, 术前eGFR< 90 mL/(min· 1.73 m2)(P=0.025)和肿物位于肾盂(P=0.049)也与UTUC患者肌层浸润相关, OR值分别为3.14(95%CI:1.16~8.54)和3.35(95%CI:1.01~11.19)。推测术前eGFR低者合并肌层浸润可能性大的原因是:(1)慢性肾病本身是UTUC的高危因素之一[14], 此类患者疾病进展时间可能较长; (2)患侧UTUC致患侧肾积水也有可能引起肾功能下降, 这是肿瘤进展到晚期的表现。肿瘤位于肾盂的患者, 可能因肾积水较输尿管尿路上皮癌患者发生晚而更晚就诊, 本研究结果也显示, 肿瘤位于肾盂与肌层浸润相关, 与文献报道相符[9]。输尿管镜活检虽然对判断UTUC是否存在肌层浸润的失败率较高且准确率较差, 但输尿管镜活检病理级别可以预测肿瘤浸润肌层的风险。

3.3 输尿管镜对UTUC肿瘤多灶性的判断

除UTUC患者的肿瘤病理级别和分期, 肿瘤是否为多发病灶对于患者是否可行KSS治疗也至关重要。Yamany等[15]报道, 输尿管镜检查会在1/4的患者中漏掉多发病灶, 且漏掉的多发病灶中47%是原位癌。本研究中有15.4%的多发病灶患者被漏诊, 比例低于Yamany等[15]的报道。值得注意的是, 本组中20例输尿管镜活检报告为多发病灶的患者, 术后病理证实为多发病灶者只有3例, 其余17例均为单发病灶, 出现此现象的原因可能为输尿管镜检时难以区别同一蒂上长出的菜花样肿物和临近的多发病灶, 故均认为是多发病灶。输尿管镜对UTUC肿瘤多灶性的判断较差, 如何提高UTUC患者多灶性的术前诊断准确率还需要进一步研究。

3.4 术前是否应该选择输尿管镜检查

临床上, UTUC患者RNU术前进行输尿管镜检查的目的有两个:(1)对于术前诊断不典型的患者进一步明确诊断; (2)对术前诊断明确考虑KSS的患者确定手术指征。

《欧洲泌尿外科学会指南》推荐对于肿物较小、CT表现不典型或分期较早的可疑UTUC患者行输尿管镜活检更为合适[4]。因为在上尿路肿物中尿路上皮癌占绝大部分, 虽然存在如肾源性腺瘤、炎性息肉以及血凝块等少见情况, 但基本可以通过术前典型的影像学特征进行区分[16]。典型的UTUC会在尿路造影检查平扫期显示为肾盂或输尿管的略低密度影, 可伴肾积水; 增强期有轻度强化, 可有延迟增强; 排泌期有边缘不整的充盈缺损。一篇meta分析显示, 在血尿患者中, 尿路造影检查发现UTUC患者的敏感性高达96%, 特异性高达99%[17]。若再结合尿液细胞学检查、尿膀胱癌抗原等化验, 术前UTUC的确诊将更加确切。相反, 术前输尿管镜活检的诊断准确性反而不高。本研究输尿管镜活检对肿物类型判断的失败率达到11.8%, 准确率只有85.2%, 因此, 对于肿物较小, CT不典型或分期较早的患者行输尿管镜检查及活检更为合适, 对于CT特征典型或临床分期较晚, 尿液细胞学检查阳性或尿膀胱癌抗原阳性者, 则不需要行输尿管镜活检进行确诊。

近10年来, 随着肾癌KSS治疗方式的临床推广, 人们逐渐意识到, 即使对术前肾功能正常的人群, KSS也具有一定的意义, 它可以降低长期心血管不良事件的发生率[18]。因此, 如何在保证肿瘤学预后的前提下, 尽可能地保留肾单位是泌尿外科医生新的挑战。UTUC的KSS通常需要准确的术前危险分层。Seisen等[3]报道, 只有低级别、非肌层浸润性的UTUC, 内镜下行保肾腔内治疗才和RNU有一致的肿瘤特异性生存率(cancer specific survival, CSS)。因此, 在术前确切地将低级别、非肌层浸润的患者从所有UTUC患者中区分出来非常重要。

虽然输尿管镜活检会延长患者的手术等待时间, 但有研究表明这并不会对患者预后造成影响[19, 20]。另外, 有学者担心输尿管镜检查会造成UTUC尿路种植或血型播散。Hendin等[21]分析了96例RNU术前行或未行输尿管镜检查的患者, 发现术前输尿管镜活检对患者的总体生存率和转移率无明显影响。虽然近期也有报道称输尿管镜检查是UTUC术后膀胱复发的独立危险因素[22], 但其结论仍需进一步前瞻性研究证实。

本研究存在一些不足之处, 比如研究为回顾性研究, 难以估计偏倚程度, 并且样本量相对较小, 需进一步扩大样本量验证结论。此外, 本研究的输尿管镜检查和输尿管镜活检操作者不同, 输尿管镜活检和术后病理结果阅片的病理医生不同, 可能会造成偏倚, 但也正因为此, 才使本研究的结论更具代表性, 而非操作者依赖。

综上所述, 术前输尿管镜活检对于判断肿瘤级别具有积极的临床意义, 可以预测肿瘤浸润肌层风险, 协助医生对UTUC进行危险分层, 但其对肿瘤多灶性判断较差, 需结合术前影像资料综合判断。

The authors have declared that no competing interests exist.

参考文献
[1] Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan[J]. Cancer, 1999, 85(6): 1342-1344. [本文引用:1]
[2] Yang MH, Chen KK, Yen CC, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan[J]. Urology, 2002, 59(5): 681-687. [本文引用:1]
[3] Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU non-muscle invasive bladder cancer guidelines panel[J]. Eur Urol, 2016, 70(6): 1052-1068. [本文引用:2]
[4] Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on upper urinary tract urothelial cell carcinoma: 2015 update[J]. Eur Urol, 2015, 68(5): 868-879. [本文引用:2]
[5] Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney di-sease[J]. J Am Soc Nephrol, 2006, 17(10): 2937-2944. [本文引用:1]
[6] Baard J, de Bruin DM, Zondervan PJ, et al. Diagnostic dilemmas in patients with upper tract urothelial carcinoma[J]. Nat Rev Urol, 2017, 14(3): 181-191. [本文引用:1]
[7] Keeley FX, Kulp DA, Bibbo M, et al. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma[J]. J Urol, 1997, 157(1): 33-37. [本文引用:2]
[8] Clements T, Messer JC, Terrell JD, et al. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection[J]. J Endourol, 2012, 26(4): 398-402. [本文引用:3]
[9] Chen XP, Xiong GY, Li XS, et al. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: expe-rience from a nationwide high-volume centre in China[J]. BJU Int, 2013, 112(7): 917-924 [本文引用:7]
[10] Wason SE, Seigne JD, Schned AR, et al. Ureteroscopic biopsy of upper tract urothelial carcinoma using a novel ureteroscopic biopsy forceps[J]. Can J Urol, 2012, 19(6): 6560-6565. [本文引用:1]
[11] Guarnizo E, Pavlovich CP, Seiba M, et al. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach[J]. J Urol, 2000, 163(1): 52-55. [本文引用:1]
[12] Brien JC, Shariat SF, Herman MP, et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma[J]. J Urol, 2010, 184(1): 69-73. [本文引用:1]
[13] Favaretto RL, Shariat SF, Savage C, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma[J]. BJU Int, 2012, 109(1): 77-82. [本文引用:1]
[14] Chen JS, Lu CL, Huang LC, et al. Chronic kidney disease is associated with upper tract urothelial carcinoma: a nationwide population-based cohort study in Taiwan[J]. Medicine (Baltimore), 2016, 95(14): e3255. [本文引用:1]
[15] Yamany T, van Batavia J, Ahn J, et al. Ureterorenoscopy for upper tract urothelial carcinoma: how often are we missing lesions?[J]. Urology, 2015, 85(2): 311-315. [本文引用:2]
[16] Potretzke AM, Knight BA, Potretzke TA, et al. Is ureteroscopy needed prior to nephroureterectomy? An evidence-based algorithmic approach[J]. Url, 2016, 88: 43-48. [本文引用:1]
[17] Chlapoutakis K, Theocharopoulos N, Yarmenitis S, et al. Performance of computed tomographic urography in diagnosis of upper urinary tract urothelial carcinoma, in patients presenting with hematuria: systematic review and meta-analysis[J]. Eur J Radiol, 2010, 73(2): 334-338. [本文引用:1]
[18] Capitanio U, Terrone C, Antonelli A, et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function[J]. Eur Urol, 2015, 67(4): 683-689. [本文引用:1]
[19] Sundi D, Svatek RS, Margulis V, et al. Upper tract urothelial carcinoma: impact of time to surgery[J]. Urol Oncol, 2012, 30(3): 266-272. [本文引用:1]
[20] Nison L, Rouprêt M, Bozzini G, et al. The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database[J]. World J Urol, 2013, 31(1): 69-76. [本文引用:1]
[21] Hendin BN, Streem SB, Levin HS, et al. Impact of diagnostic ureteroscopy on long-term survival in patients with upper tract transitional cell carcinoma[J]. J Urol, 1999, 161(3): 783-785. [本文引用:1]
[22] Liu P, Su XH, Xiong GY, et al. Diagnostic ureteroscopy for upper tract urothelial carcinoma is independently associated with intravesical recurrence after radical nephroureterectomy[J]. Int Braz J Urol, 2016, 42(6): 1129-1135. [本文引用:1]